Category: 3. Business

  • IonQ Achieves Top 10 Ranking in Prestigious Fortune Future 50 List of Global Enterprise Companies

    IonQ Achieves Top 10 Ranking in Prestigious Fortune Future 50 List of Global Enterprise Companies

    College Park, MD — October 9, 2025

    • IonQ is the only quantum company in the world to be included on distinguished list
    • Recognition highlights confidence in IonQ’s ability to grow in dynamic markets and deliver long-term value

    COLLEGE PARK, MD – October 9, 2025 – IonQ (NYSE: IONQ), the world’s leading quantum company, today announced that it has been awarded a top 10 ranking on the Fortune 2025 Future 50 list. This list recognizes companies from around the world that have superior long-term growth potential based on their strategy, technology, workforce, organizational setup, and culture. IonQ ranked eighth on this year’s list – the only quantum company in the world to be included – joining a select group of global innovators recognized for their high growth and projected long-term value.

    The Boston Consulting Group and Fortune evaluated more than 2,800 publicly traded companies with at least $5 billion in market cap and analyzed 10 million data points to identify and rank the companies on the list. IonQ’s inclusion in the top 10 places it alongside Snowflake and ahead of globally recognized tech innovators such as OpenAI, Palantir, CrowdStrike, Docusign, Shopify, and others. 

    “Being named to the Fortune Future 50 is a testament to the hard work of our team and the confidence of our partners, investors, and customers,” said Niccolo de Masi, Chairman and CEO at IonQ. “As the leading quantum company, we’re thrilled to be named alongside many of the fastest-growing technology companies in the world. This recognition reinforces our mission to provide quantum computing, networking, and sensing solutions to fundamentally reshape how the world solves complex problems.”

    This recognition comes amid continued advancements in IonQ’s technological roadmap, global partnerships, and company growth. The company recently announced it achieved a record algorithmic qubit score of #AQ 64, which significantly outperformed IBM and competing quantum systems in multiple commercially relevant algorithms. IonQ has also significantly strengthened its patent portfolio over the last year, with its intellectual property portfolio now surpassing 1,000 licensed, owned, or controlled patents and patent applications, all building on the company’s technical achievements. 

    The Fortune Future 50 ranking also follows several other recent accolades for IonQ, including Newsweek’s Excellence Index 1000, Forbes’ list of Most Successful Mid-Cap Companies, and Built-In’s Best Midsize Places to Work in Washington, DC and Seattle.

    About IonQ
    IonQ, Inc. [NYSE: IONQ] is the world’s leading quantum company delivering solutions to solve the world’s most complex problems. IonQ’s current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems that have been helping customers and partners such as Amazon Web Services, AstraZeneca, and NVIDIA achieve 20x performance results.

    The company is accelerating its technology roadmap and intends to deliver the world’s most powerful quantum computers with 2 million qubits by 2030 to accelerate innovation in drug discovery, materials science, financial modeling, logistics, cybersecurity, and defense. IonQ’s advancements in quantum networking also position the company as a leader in building the quantum internet.

    The company’s innovative technology and rapid growth were recognized in Newsweek’s 2025 Excellence Index 1000, Forbes’ 2025 Most Successful Mid-Cap Companies list, and Built In’s 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.

    IonQ Forward-Looking Statements
    This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature are intended to identify forward-looking statements. These statements include those related to the IonQ’s quantum capabilities and plans. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ’s ability to implement its business plans, forecasts, roadmaps and other expectations, and changes in the competitive industries in which IonQ operates, including development of competing technologies. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent periodic financial report (10-Q or 10-K) filed by IonQ with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.

    Contacts

    Continue Reading

  • Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025

    October 9, 2025 7:00 am EDT


    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from its HIV treatment and prevention pipeline at the 20th European AIDS Conference (EACS 2025) taking place Oct.15-18, 2025, in Paris, France. The company’s presentations will include:

    • An oral presentation of weight and body composition at Week 48 from the Phase 3 trial ( MK-8591A-052) comparing doravirine/islatravir [DOR/ISL (100mg/0.25mg)] vs. bictegravir/emtricitabine/tenofovir alafenamide i[BIC/FTC/TAF (50mg/200mg/25mg)] for the once-daily treatment of adults with virologically suppressed HIV-1 infection on antiretroviral therapy
    • A poster presentation of fasting lipids and insulin resistance at Week 48 from two Phase 3 trials comparing DOR/ISL vs. baseline antiretroviral therapy ( MK-8591A-051) or BIC/FTC/TAF ( MK-8591A-052), for the once-daily treatment of adults with virologically suppressed HIV-1 infection on antiretroviral therapy
    • An oral presentation of 96 weeks of safety and pharmacokinetics data from the Phase 2 trial ( NCT05052996) of the investigational once-weekly oral combination of islatravir in combination with lenacapavir (MK-8591D) for adults with virologically suppressed HIV-1 infection on BIC/FTC/TAF
    • A poster presentation of MK-8527 Phase 1 safety and pharmacokinetics data in adults with moderate or severe renal impairment ( MK-8527-008); MK-8527 is Merck’s investigational once-monthly pill for HIV pre-exposure prophylaxis (PrEP)

    “We are pleased to share new data from across our HIV pipeline at EACS 2025, including additional analyses from the Phase 3 program of the investigational once-daily, two-drug treatment regimen, DOR/ISL, which is currently under review with the U.S. Food and Drug Administration,” said Dr. Luisa Stamm, associate vice president and HIV section head at Merck Research Laboratories. “By advancing multiple investigational agents for daily and weekly treatments and monthly oral prevention, we aim to give individuals new and different ways to treat and prevent HIV.”

    Select abstracts in the EACS 2025 program include:

    Abstract Title and Author

    Date and Time

    HIV TREATMENT

    Weight and Body Composition After Switch to Doravirine/Islatravir (100mg/0.25mg) Once Daily from BIC/FTC/TAF in Adults Living With HIV-1: Week 48 Results from a Randomized, Double-Blind Phase 3 Study. Orkin, C, et al.

    Oral Presentation​

    Thursday, October 16, 2025,​

    11:00 – 12:00

    Evaluation of Fasting Lipids and Insulin Resistance After Switch to Doravirine/Islatravir (100mg/0.25mg) Once Daily: Week 48 Results From Two Randomized Phase 3 Studies in Adults Living With HIV‑1. Calmy, A, et al.

    Moderated ePoster​

    Friday, October 17, 2025,​

    15:35 – 16:10

    Oral Weekly Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV-1: 96 Week Outcomes from a Phase 2 Study. Colson, A, et al.

    Oral Presentation

    Saturday, October 18, 2025

    09:15 – 10:15

    Patient-Reported Outcomes From People With HIV-1 Receiving Once-Weekly Oral Islatravir in Combination With Lenacapavir: Phase 2 Week 48 Results. Eron, J, et al.

    ePoster

    HIV PREVENTION

    Pharmacokinetics and Safety of MK-8527 in Adults With Moderate or Severe Renal Impairment, Carstens, R, et al.

    ePoster

    This year at EACS, Merck will host a policy symposium “Ending the Epidemic in Europe: Policy Challenges and Opportunities” on Thursday, October 16, from 18:00 – 19:30 CEST. Merck will also host a medical symposium “Optimization of HIV Care” on Friday, Oct. 17, from 12:30 – 14:00 CEST. Both events will be open to all registered attendees.

    For more details about Merck’s clinical development program in HIV treatment and prevention, click here.

    Merck’s Commitment to HIV

    For more than 35 years, Merck has been committed to scientific research and discovery in HIV leading to scientific breakthroughs that have helped change HIV treatment. Our work has helped pioneer the development of new options across multiple drug classes to help those impacted by HIV. Today, we are developing a series of antiviral options designed to help people manage their HIV and to help prevent HIV, with the goal of reducing the growing burden of infection worldwide. We want to ensure people are not defined by HIV, and our work focuses on transformational innovations, collaborations with others in the global HIV community, and access initiatives aimed at helping to end the HIV epidemic for everyone.

    Indications and usage for PIFELTRO® (doravirine) and DELSTRIGO® (doravirine, lamivudine, and tenofovir disoproxil fumarate) in the U.S.

    PIFELTRO is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in adult patients with no prior ARV treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine.

    DELSTRIGO is indicated as a complete regimen for the treatment of HIV-1 infection in adult patients with no prior ARV treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO.

    Selected Safety Information

    Warning: Posttreatment Acute Exacerbation of Hepatitis B Virus (HBV) for DELSTRIGO

    All patients with HIV-1 should be tested for the presence of HBV before initiating ARV therapy. Severe acute exacerbations of HBV have been reported in people with concomitant HIV-1 and HBV who have discontinued products containing lamivudine or tenofovir disoproxil fumarate (TDF), which are components of DELSTRIGO. Patients coinfected with HIV-1 and HBV who discontinue DELSTRIGO should be monitored with both clinical and laboratory follow-up for at least several months after stopping DELSTRIGO. If appropriate, initiation of anti-HBV therapy may be warranted.

    Contraindications

    PIFELTRO and DELSTRIGO are contraindicated when coadministered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers (including the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and phenytoin; the androgen receptor inhibitor enzalutamide; the antimycobacterials rifampin and rifapentine; the cytotoxic agent mitotane; and the herbal product St. John’s wort (Hypericum perforatum)), as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of DELSTRIGO and PIFELTRO.

    DELSTRIGO is contraindicated in patients with a previous hypersensitivity reaction to lamivudine.

    Warnings and Precautions

    Severe Skin Reactions

    Severe skin reactions, including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), have been reported during the postmarketing experience with doravirine-containing regimens. Discontinue PIFELTRO or DELSTRIGO, and other medications known to be associated with severe skin reactions, immediately if a painful rash with mucosal involvement or a progressive severe rash develops. Clinical status should be closely monitored, and appropriate therapy should be initiated.

    New or Worsening Renal Impairment

    Renal impairment, including cases of acute renal failure and Fanconi syndrome, have been reported with the use of TDF. DELSTRIGO should be avoided with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple NSAIDs). Cases of acute renal failure after initiation of high-dose or multiple NSAIDs have been reported in people living with HIV with risk factors for renal dysfunction who appeared stable on TDF.

    Prior to or when initiating DELSTRIGO, and during treatment, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus. Discontinue DELSTRIGO in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome. Discontinue DELSTRIGO if estimated creatinine clearance declines below 50 mL/min.

    Bone Loss and Mineralization Defects

    In clinical trials in adults living with HIV, TDF was associated with slightly greater decreases in bone mineral density (BMD) and increases in biochemical markers of bone metabolism. Serum parathyroid hormone levels and 1,25 Vitamin D levels were also higher. Cases of osteomalacia associated with proximal renal tubulopathy have been reported with the use of TDF. The effects of TDF-associated changes in BMD and biochemical markers on long-term bone health and future fracture risk in adults are unknown.

    Immune Reconstitution Syndrome

    Immune reconstitution syndrome can occur, including the occurrence of autoimmune disorders with variable time to onset, which may necessitate further evaluation and treatment.

    Drug Interactions

    Because DELSTRIGO is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.

    Coadministration of PIFELTRO with efavirenz, etravirine, or nevirapine is not recommended.

    If DELSTRIGO is coadministered with rifabutin, take one tablet of DELSTRIGO once daily, followed by one tablet of doravirine (PIFELTRO) approximately 12 hours after the dose of DELSTRIGO.

    If PIFELTRO is coadministered with rifabutin, increase PIFELTRO dosage to one tablet twice daily (approximately 12 hours apart).

    Consult the full Prescribing Information prior to and during treatment for more information on potential drug-drug interactions.

    Dosage and Administration/Specific Populations

    Renal Impairment

    Because DELSTRIGO is a fixed-dose combination tablet and the dosage of lamivudine and TDF cannot be adjusted, DELSTRIGO is not recommended in patients with estimated creatinine clearance less than 50 mL/min.

    Adverse Reactions

    The most common adverse reactions with DELSTRIGO (incidence ≥5%, all intensities) were dizziness (7%), nausea (5%), and abnormal dreams (5%). The most common adverse reactions with PIFELTRO (incidence ≥5%, all intensities) were nausea (7%), dizziness (7%), headache (6%), fatigue (6%), diarrhea (6%), abdominal pain (5%), and abnormal dreams (5%).

    By week 96 in DRIVE-FORWARD, 2% of adult participants in the PIFELTRO group and 3% in the darunavir+ritonavir (DRV+r) group had adverse events leading to discontinuation of study medication.

    By week 96 in DRIVE-AHEAD, 3% of adult participants in the DELSTRIGO group and 7% in the efavirenz (EFV)/emtricitabine (FTC)/TDF group had adverse events leading to discontinuation of study medication.

    In DRIVE-FORWARD, mean changes from baseline at week 48 in LDL-cholesterol (LDL-C) and non-HDL-cholesterol (non-HDL-C) were pre-specified. LDL-C: -4.6 mg/dL in the PIFELTRO group vs 9.5 mg/dL in the DRV+r group. Non-HDL-C: -5.4 mg/dL in the PIFELTRO group vs 13.7 mg/dL in the DRV+r group. The clinical benefits of these findings have not been demonstrated.

    In DRIVE-AHEAD, mean changes from baseline at week 48 in LDL-C and non-HDL-C were pre-specified. LDL-C: -2.1 mg/dL in the DELSTRIGO group vs 8.3 mg/dL in the EFV/FTC/TDF group. Non-HDL-C: -4.1 mg/dL in the DELSTRIGO group vs 12.7 mg/dL in the EFV/FTC/TDF group. The clinical benefits of these findings have not been demonstrated.

    In DRIVE-SHIFT, mean changes from baseline at week 24 in LDL-C and non-HDL-C were pre-specified. LDL-C: -16.3 mg/dL in the DELSTRIGO group vs -2.6 mg/dL in the PI + ritonavir group. Non-HDL-C: -24.8 mg/dL in the DELSTRIGO group vs -2.1 mg/dL in the PI + ritonavir group. The clinical benefits of these findings have not been demonstrated.

    In DRIVE-AHEAD, neuropsychiatric adverse events were reported in the three pre-specified categories of sleep disorders and disturbances, dizziness, and altered sensorium. Twelve percent of adult participants in the DELSTRIGO group and 26% in the EFV/FTC/TDF group reported neuropsychiatric adverse events of sleep disorders and disturbances; 9% in the DELSTRIGO group and 37% in the EFV/FTC/TDF group reported dizziness; and 4% in the DELSTRIGO group and 8% in the EFV/FTC/TDF group reported altered sensorium.

    The safety of DELSTRIGO in virologically-suppressed adults was based on week 48 data from participants in the DRIVE-SHIFT trial. Overall, the safety profile in virologically-suppressed adult participants was similar to that in participants with no ARV treatment history.

    Serum ALT and AST Elevations: In the DRIVE-SHIFT trial, 22% and 16% of participants in the immediate switch group experienced ALT and AST elevations greater than 1.25 X ULN, respectively, through 48 weeks on DELSTRIGO. For these ALT and AST elevations, no apparent patterns with regard to time to onset relative to switch were observed. One percent of participants had ALT or AST elevations greater than 5 X ULN through 48 weeks on DELSTRIGO. The ALT and AST elevations were generally asymptomatic, and not associated with bilirubin elevations. In comparison, 4% and 4% of participants in the delayed switch group experienced ALT and AST elevations of greater than 1.25 X ULN through 24 weeks on their baseline regimen.

    Pregnancy/Breastfeeding

    There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to PIFELTRO or DELSTRIGO during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.

    Inform individuals with HIV-1 infection of the potential risks of breastfeeding, including: (1) HIV-1 transmission (in HIV-1–negative infants), (2) developing viral resistance (in HIV-1–positive infants), and (3) serious adverse reactions in a breastfed infant similar to those seen in adults.

    About Merck

    At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

    Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

    This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

    Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

    The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

    Please see Prescribing Information for PIFELTRO (doravirine) at: https://www.merck.com/product/usa/pi_circulars/p/pifeltro/pifeltro_pi.pdf and Patient Information for PIFELTRO at: https://www.merck.com/product/usa/pi_circulars/p/pifeltro/pifeltro_ppi.pdf

    Please see Prescribing Information for DELSTRIGO (doravirine, lamivudine, and tenofovir disoproxil fumarate) at: https://www.merck.com/product/usa/pi_circulars/d/delstrigo/delstrigo_pi.pdf and Patient Information for DELSTRIGO at: https://www.merck.com/product/usa/pi_circulars/d/delstrigo/delstrigo_ppi.pdf

    i bictegravir/emtricitabine/tenofovir alafenamide (BIKTARVY) is a registered trademark of Gilead Sciences, Inc.


    Source: Merck & Co., Inc.


    Continue Reading

  • Securing Africa’s Energy Future: Building Robust Energy Security Data Systems – Event

    Securing Africa’s Energy Future: Building Robust Energy Security Data Systems – Event

    Africa’s energy security is increasingly shaped by volatile global fuel markets, climate extremes, infrastructure constraints, and rapid electrification. Timely, interoperable, and trustworthy data are the backbone of effective responses, supporting early‐warning signals, contingency planning, affordability measures, and resilient investment. Yet, across many African Member States, energy security data remain fragmented across institutions, captured with heterogeneous definitions, and disseminated with time lags that blunt policy impact.

    African Energy Commission (AFREC) and the International Energy Agency (IEA) propose a joint webinar to facilitate a dialogue on how African countries can strengthen energy security data systems. The session will showcase data collection tools and templates aligned with International Standards (IRES/SIEC) and examples of short‑term energy security indicators that can be developed for the region. The webinar will be an opportunity to identify priority areas for capacity development activities among Member States.

    Webinar objectives

    • Highlight the importance of energy security data among stakeholders in Africa.

    • Explain how African Member States can strengthen their energy security data systems and transform the data into useful indicators for policy development.

    • Showcase the progress of specific African countries in collecting and using energy security data, including lessons learned.

    Continue Reading

  • Public consultation on joint guidelines on the interplay between DMA and GDPR

    Public consultation on joint guidelines on the interplay between DMA and GDPR

    The European Commission and the European Data Protection Board (EDPB) have launched a public consultation to gather feedback on draft guidelines on the interplay between the Digital Markets Act (DMA) and the General Data Protection Regulation (GDPR). 

    The guidelines will aid companies to interpret and comply with the two sets of rules and the points in which they intersect. This includes provisions in the DMA on the combination and portability of users’ data, which involve processing personal data and therefore require compliance with GDPR. Also, the DMA foresees alternative app stores and distribution channels for apps, for which gatekeepers may put in place strictly necessary and proportionate measures that must also comply with GDPR.

    This collaboration, which started in September 2024, aims to improve legal clarity and certainty for businesses in the EU, while ensuring the effectiveness of both sets of rules. The two sets of rules will be applied coherently, in full respect of the distinct competences of each body. 

    Interested parties have until 4 December 2025 to submit their input. 

    Following the assessment of the feedback collected, the final Guidelines will be adopted in 2026. 

    After the closing of the consultation, all submissions will be published on the DMA website to which a link will be included on the EDPB website.

    Continue Reading

  • Scientists urged to demand independent governance in Horizon Europe

    The chair of an expert group charged with advising the European Commission on the next Framework Programme for research and innovation has called for a campaign of “scientific activism” to implement independent governance models across the programme.

    The European Research Council (ERC) is “the jewel of the crown” of EU research funding thanks to its independent Scientific Council, which draws up its own work programmes, Manuel Heitor said during a panel on competitiveness through frontier research organised by the ERC and the University of Copenhagen on October 7.

    The former Portuguese research minister was more critical of the collaborative instruments in Horizon Europe and its predecessor, Horizon 2020. The Framework Programme “has become an excellent tool to distribute money, but it is not necessarily the best tool to do science, or to address industrial competitiveness, or to address emerging societal challenges,” he said.

    According to his advisory group’s report, collaborative projects accounted for 78% of funding under Horizon 2020 and involved 11 participants on average, each receiving average funding of €127,000 over approximately three years. The remaining 22% of funds, which mostly support single beneficiaries, have had a greater impact, largely thanks to the ERC’s autonomy, Heitor said.

    He urged the scientific community to speak to citizens and national and EU policymakers to show that the ERC is a “clear example of how to govern the rest of the Framework Programme.”

    His report recommended strengthening the independence of the European Innovation Council and creating two new councils with independent boards, one on industrial competitiveness and technology, and the other on societal challenges, to steer collaborative research. However, this idea was not picked up by the Commission in its proposal for the post-2027 Horizon Europe programme.

    Instead, there are concerns that collaborative research and innovation will come under even closer control by the Commission, which plans to link calls to the funding priorities of the future European Competitiveness Fund.

    It’s also unclear what the push to simplify the EU funding landscape will mean for the ERC. Its president, Maria Leptin, previously expressed concern that plans for a single rulebook to be applied across Horizon Europe and the Competitiveness Fund would restrict the ERC’s flexibility to implement its own processes. However, in a recent interview with Science|Business, Leptin revealed that the ERC had received reassurance from the Commission that it would not fall under a common rulebook.

    In June, before the Commission presented its proposal for the continuation of Horizon Europe, the ERC’s Scientific Council sent a letter to its president, Ursula von der Leyen, and research Commissioner Ekaterina Zaharieva requesting even greater independence and a stable, long-term budget.

    Protecting fundamental research

    During the Copenhagen conference, Denmark’s science minister, Christina Egelund, underlined the importance of “bold investments in innovation,” starting with fundamental research. The Danish presidency “will make sure to bring [Horizon Europe] negotiations forward and not to lose sight of frontier research,” she said.

    This is reflected in the Commission’s proposal for the next Horizon Europe programme, which foresees a significant budget increase for the ERC.


    Related articles


    The ERC is also at the centre of the EU’s efforts to lure disaffected scientists from the US, but speaking at the conference Leptin insisted there will be no winners from the US government’s budget cuts and assaults on academic freedom.

    “We’re all going to suffer,” she said, pointing to US cuts to climate data stations and model organism databases. “We attract these scientists over, and then we say, sorry, no databases [. . .] There is no benefit to be gained.”

    Until the US situation improves, Europe should offer scientists a “haven,” in a “non-selfish manner,” Leptin said. “If they come and spend half time here, that’s enough, that reinforces collaboration.”

    Lottery funding

    The following day, Copenhagen hosted a life science summit under the Danish presidency of the EU Council, where competitiveness was once again on the agenda.

    Europe needs more fundamental research, but it also needs bold ideas to make public funding more efficient, said Margrethe Vestager, former commissioner for competition and now chair of the board of the Technical University of Denmark.

    “There are so many great ideas for the public funding, and I think it feels like a lottery as to whether you get it or not, so why not make it a lottery?” she said. “Then, if you don’t get funding that year, you can get more points, so you have a better chance the next year.”

    The objective should be to reduce the time and resources required to obtain funding, she added. 

    The Commission has made simplification a priority, and Zaharieva has said it is “exploring” the idea of introducing lottery funding in the next iteration of Horizon Europe.

    Continue Reading

  • PepsiCo (PEP) Q3 2025 earnings

    PepsiCo (PEP) Q3 2025 earnings

    FILE PHOTO: Cans of Pepsi are seen at the PepsiCo Walkers factory in Leicester, Britain, August 14, 2024. 

    Hollie Adams | Reuters

    PepsiCo on Thursday reported quarterly earnings and revenue that beat analysts’ expectations, as international growth offset another quarter of declining volume in North America.

    Here’s what the company reported for its fiscal third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:

    • Earnings per share: $2.29 adjusted vs. $2.26 expected
    • Revenue: $23.94 billion vs. $23.83 billion expected

    Pepsi reported third-quarter net income attributable to the company of $2.6 billion, or $1.90 per share, down from $2.93 billion, or $2.13 per share, a year earlier.

    Excluding items, the company earned $2.29 per share.

    Net sales rose 2.6% to $23.94 billion. Stripping out acquisitions, divestitures and foreign exchange, Pepsi’s organic revenue increased 1.3% in the quarter.

    However, the Frito-Lay and Gatorade owner is still seeing softer demand for its products. Pepsi’s worldwide volume for both food and drinks fell 1% during the quarter. The metric strips out pricing and foreign exchange changes.

    In particular, Pepsi has struggled in its home market in recent quarters, leading the company to invest back into its brands and to explore cost-cutting measures.

    Pepsi Foods North America, which includes brands like Doritos, Quaker Oats and Pearl Milling, reported that its volume fell 4% in the fiscal third quarter. And Pepsi’s North American beverage unit saw volume shrink 3%, although CEO Ramon Laguarta noted “improved momentum” in the business.

    The company also reiterated its full-year outlook. It still expects its core constant currency earnings per share to be roughly unchanged from the prior year and organic revenue to grow by a low single-digit percentage.

    Pepsi also announced on Thursday that Chief Financial Officer Jamie Caulfield plans to retire. Walmart U.S. CFO Steve Schmitt will succeed him, effective Nov. 10.

    Continue Reading

  • Wind power giant Orsted to slash 2,000 jobs over next two years

    Wind power giant Orsted to slash 2,000 jobs over next two years

    Picture taken on September 4, 2023 shows windmills at the Nysted Offshore Wind Farm constructed by Danish windpower giant Orsted in 2002-2003 in the Baltic Sea near Gedser in Denmark.

    Thomas Traasdahl | Afp | Getty Images

    Beleaguered wind farm operator Orsted announced Thursday that it intends to cut up to 2,000 jobs toward the end of 2027, in a bid to become more competitive and refocus its efforts on Europe.

    The company has faced headwinds this year as President Donald Trump’s administration clamped down on wind power generation in the United States.

    Orsted’s shares were 1% higher in early European trade on Thursday.

    This is a developing story. Please refresh for updates.

    Continue Reading

  • Fast SPECT acquisitions for single time-point dosimetry in 177Lu-PSMA for metastatic castration-resistant prostate cancer (mCRPC) patients | Egyptian Journal of Radiology and Nuclear Medicine

    Fast SPECT acquisitions for single time-point dosimetry in 177Lu-PSMA for metastatic castration-resistant prostate cancer (mCRPC) patients | Egyptian Journal of Radiology and Nuclear Medicine

    In this study, the calibration factor necessary for quantitative SPECT analysis was derived by dividing the known activity concentration. For the dosimetric calculation, the STP voxel-based dosimetry using the Hanschied approach was employed to calculate the absorbed dose in the kidneys and tumours based on the SPECT images acquired approximately 48 hours after administration.

    The mean and SD of kidney absorbed dose were 2.04 Gy ± 0.37 Gy (range 1.71 to 2.67 Gy). The absorbed doses within tumours showed considerable variation across the twenty-five tumours analysed, which were derived from eight treatment cycles. Tumour absorbed doses ranged from a low of 0.98 Gy to a high of 16.05 Gy. The mean absorbed dose to the tumours was 5.14 Gy, the SD was 3.81 Gy, as detailed in the box plot in Figure 3.

    Fig. 3

    Box plot of absorbed dose in Gy to (left) kidneys and (right) tumours

    Quantitative voxel-based dosimetry was carried out for five patients (P1–P5) over eight treatment cycles (C1–C8), with imaging acquisition performed between 48 and 52 hours post-therapy. The absorbed radiation doses to the kidneys and selected tumour sites are summarised in Table 2.

    Table 2 Absorbed dose to kidneys and Tumours for Each Patient

    Kidney absorbed dose

    Across all patients, the kidney absorbed doses remained within a relatively narrow range, suggesting consistent radiopharmaceutical handling and organ tolerance. For Patient P1, who underwent three treatment cycles (C1–C3), the kidney dose started at 1.99 Gy in C1, rose to 2.66 Gy in C2, and then dropped slightly to 2.23 Gy in C3. This fluctuation may reflect changes in bio-distribution or renal clearance over time.

    Patients P2 and P3, each evaluated during one or two cycles (C4–C6), had similar kidney doses, consistently measured at 1.71 Gy, despite variation in tumour load and lesion location. Patient P4 (C7) received 1.88 Gy, while Patient P5 (C8) had the highest kidney dose at 2.46 Gy. Notably, none of the patients exceeded the generally accepted renal threshold, supporting the safety of the administered activity levels in this cohort.

    Tumour absorbed dose

    Tumour dosimetry revealed a broader range of absorbed doses, reflecting both inter-patient and intra-patient variation. In Patient P1, lung lesions demonstrated a downward trend across three consecutive cycles, with the left lung receiving 8.54 Gy, 7.67 Gy, and 4.20 Gy in C1, C2, and C3, respectively. Similarly, the right lung showed a decrease from 5.92 Gy to 3.17 Gy. This decline likely indicates therapeutic response, consistent with expectations following multiple cycles of targeted radionuclide therapy (as illustrated in Figure 4).

    Fig. 4
    figure 4

    A 64-year-old male with metastatic castration-resistant prostate cancer (mCRPC). Post 177Lu-PSMA therapy showing a 1st cycle in December 2023, b 2nd cycle in March 2024, and c 3rd cycle in June 2024. Whole-body SPECT/CT at 48 hours post-administration demonstrates good tracer uptake in multiple lungs, left adrenal, and bone metastases, with physiological uptake in salivary glands, liver, spleen, and bowel. Markings indicate a decrease in lung lesions across treatment cycles

    Patient P2 showed tumour doses between 1.93 and 5.53 Gy in spinal and rib lesions. Though the absorbed doses remained moderate, a slight decrease was observed in the second cycle (C5), particularly in the rib and sternum, which may suggest early response to treatment or subtle changes in radiotracer uptake.

    In Patient P3 (C6), tumour absorbed doses were lower and more uniform, ranging from 1.55 to 2.69 Gy, covering thoracic and lumbar vertebrae. In contrast, Patient P4 (C7) demonstrated a much higher dose to the lumbar spine, reaching 16.05 Gy, the highest tumour dose recorded in this study. Additional lesions in the lung and pelvis received 4.18 Gy and 3.76 Gy, respectively.

    Patient P5 (C8) also presented with high skeletal uptake. The lumbar spine lesion received 13.00 Gy, while T-spine and pelvic lesions ranged from 6.03 to 10.03 Gy. These findings reflect intense PSMA expression in metastatic bone lesions and underline the heterogeneity of tumour dose distribution in advanced disease.

    Continue Reading

  • Global shipping industry reaffirms support for the IMO Net Zero Framework — World Shipping Council

    9 October 2025 – London: Leading international maritime associations and organisations reiterate our strong support for adoption by the world’s governments at the UN International Maritime Organization (IMO) of the “Net-Zero Framework” at the critical Extraordinary Session of the IMO Marine Environment Protection Committee next week (14-17 October).

    The global industry remains fully committed to working collaboratively with IMO Member States to implement successfully this carefully balanced regulatory package for achieving net zero GHG emissions by or close to 2050, with necessary incentives to de-risk investment in new green marine fuels to accelerate the total decarbonisation of international shipping and to implement a just transition for the maritime workforce.

    Only global rules will decarbonise a global industry. Without the Framework, shipping would risk a growing patchwork of unilateral regulations, increasing costs without effectively contributing to decarbonisation.

    With the support of the industry, this is a unique and historic opportunity for governments to put in place a comprehensive global framework, which will be strictly enforced worldwide, to incentivise the shipping industry’s transition to net zero emissions whilst ensuring a level playing field.

    The maritime transport sector, which moves 90% of global trade, is ready to play its important part in delivering a sustainable future.  

    Read the full joint industry statement here.

    Continue Reading

  • monetary and financial stability implications

    monetary and financial stability implications

    Remarks prepared for delivery

    Introduction

    Distinguished guests, colleagues, friends. Good afternoon.

    I am very pleased to join you here at the 6th Global Fintech Fest in Mumbai – a financial hub celebrated for its rich history, vibrant culture and, most importantly, enduring spirit of innovation.

    Today, central banks operate in a world of rapid transformation. Technology has reshaped not only how financial services are delivered but also how central banks interact with external stakeholders. Artificial intelligence (AI) stands at the centre of this transformation.

    In my speech this afternoon, I will explore how central banks are using AI to support their operations, the challenges AI poses and strategies to address the trade-offs central banks encounter in order to reconcile the risks and benefits.

    Central banks have improved their operations with the use of AI

    The adoption of AI has extended to central banks, where it has the potential to enhance efficiency, improve accuracy and strengthen decision-making processes. AI is making significant impact in three key areas:

    1) Data analysis

    • Central banks are leveraging AI to unlock the potential of both traditional and non-traditional data sources. By analysing diverse data sets – from satellite imagery to social media content – AI offers new ways to understand economic activity and trends.
    • Natural language processing (NLP) and large language models (LLMs) offer central banks innovative tools to extract insights and analyse survey responses. For instance, the Bank of Canada leverages AI models along with granular data to improve the monitoring of economic activities, banknote demand and sentiment across key sectors.1

    2) Economic forecasting and policy analysis

    • Central banks use AI, alongside human expertise, to better understand economies and enhance forecasting or policy analysis.
      • For example, AI has become invaluable for nowcasting, providing real-time assessments of key economic indicators such as GDP growth and inflation. AI analyses consumption patterns and detects supply chain bottlenecks in real time, offering a clearer understanding of economic dynamics.2
    • Machine learning models process vast data sets, uncovering trends and behaviours that often go unnoticed. For example, fine-tuned open source LLMs summarise economic narratives and predict recessions. Neural networks can also leverage detailed data sets to capture complex non-linear relationships, providing valuable insights during periods of rapidly changing inflation dynamics.
    • AI supports financial stability analysis by identifying patterns in large data sets, which is useful for assessing risks across financial and non-financial firms. For example, during low liquidity and periods of market dysfunction, AI supports predictions by monitoring market anomalies.

    3) Payment system oversight and global connectivity

    • AI is transforming payment systems by enhancing safety, efficiency and compliance. Tools like graph neural networks improve fraud detection by identifying suspicious transaction networks, especially when data are securely pooled across institutions or jurisdictions.
    • In correspondent banking, which faces challenges from compliance risks, AI could enhance anti-money laundering (AML) and know-your-customer (KYC) processes, reducing risks and their associated costs, which may restore global payment connectivity. By pooling payment data across jurisdictions, AI strengthens cross-border fraud detection and compliance.
    • Central banks are adopting AI to enhance payment infrastructures. The BIS Innovation Hub is collaborating with seven central banks, including the Bank of France, Bank of Japan, Bank of Korea and Swiss National Bank, on Project Agorá. This project leverages tokenisation to implement the next-generation of correspondent banking. Beyond the focus on core features of the unified ledger, AI models may be used in the future to improve efficiencies in compliance practices.

    Central banks face challenges in their policy operations

    While the benefits of AI are undeniable, its integration into central banking presents challenges, particularly in monetary policy and financial stability. Here are some pressing issues:

    1) Key technological limitations of AI

    • Despite advancements, AI models face challenges in logical reasoning and counterfactual thinking, struggling to adapt when familiar problems are rephrased. This highlights a lack of true understanding.
    • A major issue is “hallucination”, where LLMs generate plausible but incorrect information, rather than ensure factual accuracy.
    • Many AI models, particularly proprietary ones without open source frameworks, function as opaque “black boxes”. Their lack of explainability poses challenges for their application in monetary policy and financial stability decisions.
    • The black box nature of AI models also raises concerns about trust, accountability and compliance with ethical guidelines, compounded by legal risks around data quality, privacy and confidentiality.
    • Additional risks – referred to as “third-party dependence” – emerge from reliance on a few providers of advanced AI models, driven by the high costs of developing and deploying data-intensive systems.

    2) Monetary policy and transmission effectiveness

    AI presents several challenges to monetary policy and its transmission mechanisms, as highlighted in a recent ECB speech and our annual economic report. 3

    • AI is poised to reshape labour and capital markets, influencing income and wealth distribution. This has significant implications for monetary policy. It affects the marginal propensity to consume, consumption patterns and access to credit, all of which shape how demand responds to policy changes.
    • AI-driven algorithmic pricing enables faster and more flexible price adjustments. For instance, large retailers can quickly respond to changes in gas prices or exchange rates, or other shocks, potentially amplifying their impact on inflation. As smaller firms adopt AI, these effects could intensify, making inflation more challenging for central banks to predict and manage.
    • Faster price adjustments may also reduce the lag between policy actions and their effects on inflation. Additionally, AI-driven investments and productivity gains could change how fast and the way firms and households respond to interest rate changes.
    • Furthermore, if AI drives any shift in financial structures, such as increased non-bank intermediation, it could alter the transmission of monetary policy. Compared with traditional banks, non-banks are more responsive to measures targeting longer-term interest rates, such as asset purchases, and they tend to carry greater credit, liquidity and duration risks.

    3) Financial stability risks

    The integration of AI into financial systems presents financial stability risks that central banks and policymakers must address:

    • AI’s rapid, real-time responses may increase volatility and herding behaviour, creating destabilising feedback loops. Liquidity risks may also arise. AI models might prompt widespread liquidity hoarding and trigger fire sales, further destabilising markets.
    • As institutions increasingly rely on AI and reduce dependence on human expertise, the widespread use of similar algorithms could amplify market movements. For instance, if numerous institutions adopt comparable AI models for credit risk, trading or portfolio management, synchronised responses during periods of stress could exacerbate procyclicality and trigger large-scale asset sell-offs.
    • Algorithmic collusion is another risk. AI trained on similar data sets may unintentionally produce coordinated recommendations or pricing strategies, mimicking collusion and undermining competition. Traditional regulatory frameworks may struggle to address these challenges.

    4) Cyber risks and ethical considerations

    • Cyber criminals are increasingly leveraging AI to craft more seemingly convincing phishing emails, develop malicious code and mimic voices or writing styles. This has fuelled a surge in phishing, fraud and ransomware attacks. Additionally, AI introduces new and evolving risks, such as prompt injection and data poisoning, which can compromise training data and undermine the integrity of systems.
    • The ethical use of AI is crucial to maintaining public trust. Central banks have a responsibility to ensure that AI systems are transparent, fair and free from bias. However, AI systems can unintentionally reflect biases present in their training data, potentially leading to unfair outcomes. For example, algorithmic discrimination in credit scoring could exclude certain groups from accessing financial products, thereby exacerbating inequalities.
    • AI also raises significant concerns regarding privacy. The misuse or abuse of sensitive information poses serious risks to individuals. Financial institutions and AI providers must adopt and adhere to strict privacy standards to safeguard personal data and uphold public trust.
    • A noteworthy initiative in this area is the FREE-AI Committee Report by our colleagues at the Reserve Bank of India (RBI). The report introduces a Framework for Responsible and Ethical Enablement (FREE-AI) in the financial sector and exemplifies how central banks can lead in promoting responsible AI adoption. By addressing key ethical and operational challenges, it provides a robust and forward-looking blueprint that sets a high standard for the global central banking community. 4

    Central banks face policy trade-offs

    As central banks explore the transformative potential of AI, they face complex trade-offs that demand careful consideration:

    • One of the key decisions revolves around choosing between external and in-house AI models and data sources.
      • External models and commercial data vendors provide cost efficiency, rapid deployment and access to private sector expertise. However, they come with challenges such as reduced transparency, increased dependency on a limited number of providers and stricter usage restrictions.
      • On the other hand, in-house models and curated internal data offer greater control and adaptability but require significant investments in infrastructure, skilled personnel and robust governance frameworks.
    • Another critical challenge lies in balancing speed and accuracy. AI’s ability to enable rapid, real-time analysis is invaluable for timely decision-making. However, this speed must be tempered by efforts to mitigate risks such as hallucinations, biases and vulnerabilities like prompt injection attacks, to ensure that the insights generated are both reliable and trustworthy.
    • While the potential of AI to automate routine tasks and enhance efficiency is undeniable, human judgment remains indispensable. Central banks must cultivate teams with a balanced mix of economic expertise and technical skills to effectively oversee and interpret AI-driven insights, ensuring that human oversight complements technological advancements.

    Overall, achieving the right balance between performance, cost and control is vital for central banks to successfully adopt AI. Central banks must thoughtfully evaluate immediate short-term investments against the long-term benefits.

    The role of the BIS in supporting central banks

    So how can institutions like the BIS help central banks navigate the evolving landscape of AI? At the BIS, we provide support to central banks through three key avenues:

    1) Forum for discussion

    We offer a space for central banks to exchange insights and build a community around emerging technologies.

    • For example, our research conferences, workshops and networks explore research frontiers and provide knowledge on their implications for central banks.

    2) Platform for international cooperation

    We facilitate collaboration among central banks and regulators to uphold monetary and financial stability.

    • Through committees such as the Basel Committee on Banking Supervision and the Committee on Payments and Market Infrastructures, we address the challenges and opportunities posed by the digital revolution. This enables us to exchange best practices, forge consensus and enhance governance regimes for AI adoption.

    3) Experimental innovation

    Through the BIS Innovation Hub, we enable central banks to experiment with cutting-edge technologies.

    • For instance, Project Aurora uses AI to enhance monitoring of suspicious transactions across firms and borders.

    By fostering discussion, collaboration and experimentation, the BIS helps central banks to harness the potential of AI while mitigating risks.

    Conclusion

    To conclude, AI presents transformative opportunities for central banks, enhancing efficiency, decision-making and financial infrastructure. From advanced data analysis to improved oversight of payment systems, AI is already reshaping central bank operations. However, challenges such as data quality, model complexity, ethical concerns and financial stability risks must be carefully addressed.

    To fully realise the potential of AI, central banks must balance its benefits with its risks. Transparency, robust governance and talent development are essential to navigating this evolving landscape.

    As stewards of monetary and financial stability, central banks have a responsibility to adopt AI in a safe, ethical and sustainable manner. The BIS is dedicated to supporting this journey by fostering dialogue, promoting international cooperation and enabling innovation.

    Thank you.


    The views expressed in this speech are my own and not necessarily those of the BIS or its member central banks.

    Continue Reading